Business
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024.\n\n \n \n \n \n \n \n\n \nHighlights include:\n$9.9 million in net revenue during the second quarter of 2024, an increase of 16% sequentially from the first quarter of 2024.Adjusted earnings of $0.2 million, which represents a $0.8 million improvement over the prior period in 2024.$78.5 million in assets, $52.5 million in liabilities and $26.3 million of shareholders' equity.\"We are very optimistic about our company's future, and we look forward to building on our second quarter success throughout the remainder of the year,\" said Cumberland's CEO, A.J. Kazimi. \"Given the number of ongoing positive developments, we believe we're still on track to post significant revenue growth and positive cashflow from operations during 2024.\"\nRECENT DEVELOPMENTS INCLUDE: \nKristalose® Medicaid Coverage & Gastroenterology Guidelines Recommendation\nWisconsin has added Kristalose, Cumberland's prescription-strength laxative, to its Medicaid formulary, and Cumberland is implementing a special initiative to announce this development in that market. Cumberland also has Medicaid coverage for the brand in New York state and Texas, two of the largest states for the product.\nAdditionally, the American Gastroenterological Association's (\"AGA\") guidelines include Kristalose as a first-line treatment option for opioid-induced constipation. As the guidelines state, \"Constipation is by far the most common and debilitating gastrointestinal effect of opioids, and some degree of constipation is near universal in patients taking opioid medications.\" Cumberland believes the AGA's recommendation will support the use of Kristalose in those patients.\nNew Study Supports Vibativ® as an Effective Treatment for Anthrax Infections \nIn June, Antimicrobial Agents and Chemotherapy published a study evaluating Vibativ (telavancin) as a novel therapeutic against anthrax inhalation, the most dangerous form of those infections. Researchers were particularly interested in finding alternatives to current antibiotics in case anthrax bacteria become resistant to them.\nResearchers tested telavancin against 17 ...